Milameline: Nonselective, Partial Muscarinic Receptor Agonist for the Treatment of Alzheimer's Disease?
Open Access
- 7 June 2006
- journal article
- Published by Wiley in CNS Drug Reviews
- Vol. 5 (2), 93-104
- https://doi.org/10.1111/j.1527-3458.1999.tb00092.x
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effectsBrain Research, 1998
- Comments on the pathogenesis of muscarinic agonist-induced corneal opacities in ratsFood and Chemical Toxicology, 1996
- Toxicological comparison of a muscarinic agonist given to rats by gavage or in the dietFood and Chemical Toxicology, 1996
- Cell Surface Receptor Mediated Control of Amyloid Precursor Protein Secretion: Involvement of Pleiotropic Signal Transduction CascadesPublished by Springer Nature ,1995
- The Target Population in Phase I Clinical Trials of Cholinergic Compounds in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1995
- Inflammatory mechanisms in Alzheimer's diseaseTrends in Pharmacological Sciences, 1994
- Cholinergic innervation of the amygdaloid complex in the human brain and its alterations in old age and Alzheimer's diseaseJournal of Comparative Neurology, 1993
- Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's diseasePublished by Elsevier ,1993
- Muscarinic Receptors—Characterization, coupling and functionPharmacology & Therapeutics, 1993
- Nomenclature of amyloid A4 proteins and their precursors in Alzheimer's disease and down's syndromeNeurobiology of Aging, 1990